The Role of MiR-152 in Urological Tumors: Potential Biomarkers and Therapeutic Targets

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 28

PMID 39606232

Authors

Xin Li

Biao Qian

Xu Chen

Maolei Shen

Shankun Zhao

Xinsheng Zhang

Jian He

Affiliations

Soon will be listed here.

Abstract

Urological malignant tumors pose a significant threat to human health, with a high incidence rate each year. Prostate cancer, bladder cancer, and renal cell carcinoma are among the most prevalent and extensively researched urological malignancies. Despite advancements in research, the prognosis for these tumors remains unfavorable due to late detection, postoperative recurrence, and treatment resistance. A thorough investigation into their pathogenesis is crucial for early diagnosis and treatment. Recent studies have highlighted the close association between microRNAs (miRNAs) and cancer progression. miRNAs are small non-coding RNAs composed of 19-23 nucleotides that regulate gene expression by binding to the 3' untranslated region (3'UTR) of target mRNAs, impacting key cellular processes such as proliferation, differentiation, apoptosis, and migration. Dysregulation of miRNAs can disrupt the expression of oncogenes and tumor suppressor genes, contributing to cancer development. Among the various miRNAs studied, miR-152 has garnered attention for its role in urological malignancies. Several studies have indicated that dysregulation of miR-152 expression is significant in these cancers, warranting a comprehensive review of the evidence. This review focuses on the expression and function of miR-152 in prostate cancer, bladder cancer, and renal cell carcinoma, elucidating its mechanisms in cancer progression and exploring its potential as a therapeutic target and biomarker in urological malignancies.

References

Ying X, Liu B, Yuan Z, Huang Y, Chen C, Jiang X . METTL1-m G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med. 2021; 11(12):e675. PMC: 8694502. DOI: 10.1002/ctm2.675. View

Cheng Z, Ma R, Tan W, Zhang L . MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. Exp Mol Med. 2014; 46:e112. PMC: 4150934. DOI: 10.1038/emm.2014.51. View

Yin T, Zhao H . miR-152-3p impedes the malignant phenotypes of hepatocellular carcinoma by repressing roundabout guidance receptor 1. Cell Mol Biol Lett. 2022; 27(1):22. PMC: 8903719. DOI: 10.1186/s11658-022-00322-y. View

Chen J, Liao Y, Ma J, Mao Q, Jia G, Dong X . [Circulating miR-152 helps early prediction of postoperative biochemical recurrence of prostate cancer]. Zhonghua Nan Ke Xue. 2018; 23(7):603-608. View

Braconi C, Huang N, Patel T . MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51(3):881-90. PMC: 3902044. DOI: 10.1002/hep.23381. View

Scott L, Keam S . Lumasiran: First Approval. Drugs. 2021; 81(2):277-282. DOI: 10.1007/s40265-020-01463-0. View

Zhang C, Wang W, Lin J, Xiao J, Tian Y . lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. Int Braz J Urol. 2019; 45(3):549-559. PMC: 6786104. DOI: 10.1590/S1677-5538.IBJU.2018.0450. View

Yang Y, Gong P, Yao D, Xue D, He X . LncRNA Promotes Clear Cell Renal Cell Carcinoma Progression by Targeting to Upregulate . Cancer Manag Res. 2021; 13:2287-2294. PMC: 7959199. DOI: 10.2147/CMAR.S298649. View

Li S, Pan M, Wu X, Bai Y, Qi M, Chen J . miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP Bladder Cancer Cell Lines via Suppressing HMGA2 Expression. Ann Clin Lab Sci. 2023; 53(4):607-618. View

10.

Lee Y, Jeon K, Lee J, Kim S, Kim V . MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002; 21(17):4663-70. PMC: 126204. DOI: 10.1093/emboj/cdf476. View

11.

Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L . miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. Prostate. 2013; 73(10):1082-9. DOI: 10.1002/pros.22656. View

12.

Kulkarni P, Dasgupta P, Hashimoto Y, Shiina M, Shahryari V, Tabatabai Z . A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis. Cancer Res. 2021; 81(6):1500-1512. PMC: 7969457. DOI: 10.1158/0008-5472.CAN-20-0832. View

13.

Lichner Z, Fendler A, Saleh C, Nasser A, Boles D, Al-Haddad S . MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013; 59(11):1595-603. DOI: 10.1373/clinchem.2013.205450. View

14.

Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X . miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci. 2011; 56(7):2009-16. DOI: 10.1007/s10620-010-1536-3. View

15.

Mao D, Zhang X, Wang Z, Xu G, Zhang Y . TMEM97 is transcriptionally activated by YY1 and promotes colorectal cancer progression via the GSK-3β/β-catenin signaling pathway. Hum Cell. 2022; 35(5):1535-1546. DOI: 10.1007/s13577-022-00759-5. View

16.

Wu J, Chi X, Yang Q, Li J . Expression of miR-152 in cervical cancer and its influence on cisplatin resistance. Afr Health Sci. 2024; 23(2):246-255. PMC: 10782345. DOI: 10.4314/ahs.v23i2.28. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Huttelmaier S . Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology. 2015; 4(6):e1008805. PMC: 4485830. DOI: 10.1080/2162402X.2015.1008805. View

19.

Denli A, Tops B, Plasterk R, Ketting R, Hannon G . Processing of primary microRNAs by the Microprocessor complex. Nature. 2004; 432(7014):231-5. DOI: 10.1038/nature03049. View

20.

Moya L, Meijer J, Schubert S, Matin F, Batra J . Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. Int J Mol Sci. 2019; 20(5). PMC: 6429489. DOI: 10.3390/ijms20051154. View